The Holiday Season is approaching, and it is time for some reflections of the year 2024. It has been another intense year with the successful full market launch in the US of the ClearPoint Prism® Neuro Laser Therapy System for neurosurgery, followed by the announcement of a new strategic direction for CLS. We have also welcomed Peter Max as new Chairman of the Board and Peter Mantas as new Board Member.

We look forward to 2025 and are already working hard to implement our new strategic direction, with a more narrow and sharper business focus towards neurosurgery, aimed at substantially improving our ability to drive sustainable high-margin growth and financial strength.

Stay tuned for our year-end newsletter with more information to be released in the coming days!

We heartfully thank all our shareholders, collaboration partners, clinicians & patients for a great year and look forward to the future with confidence!

Merry Christmas and a Happy New Year!

The CLS Team